BAY 0 9867 Cipro Pediatric Use Study (QUIP)
A Prospective, Open-label, Non-randomized, Naturalistic, Long-term Safety Surveillance, Observational Study of Either Ciprofloxacin (Either as Oral Suspension, Oral Tablets or Sequential IV Followed by Oral Therapy or Purely IV Therapy) or a Non-quinolone Antibiotic (Either as Oral Suspension, Oral Tablets or Sequential IV Followed by Oral Therapy or Purely IV Therapy) in the Treatment of Pediatric Patients With Infectious Diagnoses
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
Quebec
-
Montreal, Quebec, Canada, H3H 1P3
-
-
-
-
Alabama
-
Mobile, Alabama, Forenede Stater, 36608
-
-
Arkansas
-
Fort Smith, Arkansas, Forenede Stater, 72903
-
-
California
-
Corona, California, Forenede Stater, 92879
-
Fountain Valley, California, Forenede Stater, 92708
-
Long Beach, California, Forenede Stater, 90806
-
Orange, California, Forenede Stater, 92868-3974
-
Pico Rivera, California, Forenede Stater, 90660
-
San Bernardino, California, Forenede Stater, 92411
-
San Luis Obispo, California, Forenede Stater, 93405
-
-
Colorado
-
Centennial, Colorado, Forenede Stater, 80112
-
Denver, Colorado, Forenede Stater, 80218
-
-
Florida
-
Ft. Walton Beach, Florida, Forenede Stater, 32548
-
Gainesville, Florida, Forenede Stater, 32610-0254
-
Hialeah, Florida, Forenede Stater, 33013
-
Jacksonville, Florida, Forenede Stater, 32209
-
Jupiter, Florida, Forenede Stater, 33458
-
Miami, Florida, Forenede Stater, 33155
-
Pensacola, Florida, Forenede Stater, 32504
-
Tampa, Florida, Forenede Stater, 33606
-
Tampa, Florida, Forenede Stater, 33607
-
-
Georgia
-
Snellville, Georgia, Forenede Stater, 30078
-
-
Hawaii
-
Honolulu, Hawaii, Forenede Stater, 96813
-
-
Idaho
-
Idaho Falls, Idaho, Forenede Stater, 83404
-
-
Illinois
-
Park Ridge, Illinois, Forenede Stater, 60068-1174
-
Springfield, Illinois, Forenede Stater, 62701
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46202
-
-
Kansas
-
Overland Park, Kansas, Forenede Stater, 66215
-
-
Kentucky
-
Bardstown, Kentucky, Forenede Stater, 40004
-
-
Louisiana
-
New Orleans, Louisiana, Forenede Stater, 70118-5799
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02115
-
-
Minnesota
-
Red Wing, Minnesota, Forenede Stater, 55066-0095
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68114
-
Omaha, Nebraska, Forenede Stater, 68131
-
-
Nevada
-
Las Vegas, Nevada, Forenede Stater, 89109
-
-
New Jersey
-
Hackensack, New Jersey, Forenede Stater, 07601-1991
-
Voorhees, New Jersey, Forenede Stater, 08043
-
-
New York
-
Bronx, New York, Forenede Stater, 10461
-
New Hyde Park, New York, Forenede Stater, 11040
-
New York, New York, Forenede Stater, 10032
-
New York, New York, Forenede Stater, 10021-4885
-
Stony Brook, New York, Forenede Stater, 11794-8111
-
-
North Carolina
-
Durham, North Carolina, Forenede Stater, 27710
-
Wilmington, North Carolina, Forenede Stater, 28401
-
-
Ohio
-
Akron, Ohio, Forenede Stater, 44308-1062
-
Cleveland, Ohio, Forenede Stater, 44109-1998
-
Dayton, Ohio, Forenede Stater, 45404-1815
-
Youngstown, Ohio, Forenede Stater, 44501-0240
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forenede Stater, 73120
-
Oklahoma City, Oklahoma, Forenede Stater, 73104
-
Tulsa, Oklahoma, Forenede Stater, 74135
-
-
Pennsylvania
-
Elverson, Pennsylvania, Forenede Stater, 19520
-
Havertown, Pennsylvania, Forenede Stater, 19083
-
-
South Carolina
-
Charleston, South Carolina, Forenede Stater, 29425
-
-
Tennessee
-
Memphis, Tennessee, Forenede Stater, 38105-2729
-
-
Texas
-
Austin, Texas, Forenede Stater, 78756
-
Benbrook, Texas, Forenede Stater, 76126
-
El Paso, Texas, Forenede Stater, 79925
-
Fort Worth, Texas, Forenede Stater, 76104
-
Galveston, Texas, Forenede Stater, 77555-0371
-
Houston, Texas, Forenede Stater, 77030
-
Houston, Texas, Forenede Stater, 77024
-
Temple, Texas, Forenede Stater, 76508
-
-
Utah
-
Layton, Utah, Forenede Stater, 84041
-
-
Virginia
-
Norfolk, Virginia, Forenede Stater, 23510
-
Richmond, Virginia, Forenede Stater, 23298
-
-
West Virginia
-
Morgantown, West Virginia, Forenede Stater, 26506
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Patient is >/= 2 months of age through 16 years of age
- A parent/caregiver must sign an informed consent
- Patient must provide assent, as appropriate based on local institutional review board guidelines
Exclusion Criteria:
Patients presenting with the following conditions:
- exacerbations of cystic fibrosis (CF)
- meningitis
- Brain abscess
- bacterial endocarditis,
- Bone and joint infections
having any of the following conditions but lacking a personal history may be admitted to the trial:
- Arthritis
- Juvenile rheumatoid arthritis (JRA)
- Rheumatoid arthritis (RA)
- Systemic lupus erythematosis (SLE)
- History of rheumatic fever
- Psoriasis
- Inflammatory bowel disease
- Osteoarthritis (OA)
- Known underlying rheumatological disease, joint problems known to be associated with arthropathy.
- Patients with any pre-treatment baseline musculoskeletal exam abnormalities
- Known risk of experiencing seizures, a history of any convulsive disorders
- Requiring any concomitant therapeutic course of systemic antibacterial agent
- Participation in any industry-sponsored clinical drug development study within one month prior to this study
- Known significant liver impairment (ALAT/ASAT and/or baseline bilirubin > 3 times upper limit of normal)
- Known significant renal insufficiency (calculated creatinine clearance of < 30 ml/min/1.73 m²)
- Are pregnant or lactating, or are sexually active and using unreliable contraception.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Ciprofloxacin
Subjects receiving Ciprofloxacin (group followed-up for 5 years)
|
Either as oral suspension, oral tablets or sequential intravenous (IV) - oral therapy or purely IV therapy according to label
|
|
Aktiv komparator: Non-quinolone antibiotic
Subjects receiving non-quinolone antibiotic (group followed-up for 2 years)
|
Common used dose and route
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of Arthropathy (Cumulative)
Tidsramme: 4-6 weeks after treatment / 1 year after treatment / 2 or 5 years after treatment
|
Arthropathy, as assessed by independent safety committee.
The committee, after reviewing data related to musculoskeletal events, decided whether each patient had arthropathy or not.
Each incidence includes number shown at previous time point, plus any new patients with the event.
The 112/20 arthropathies are mentioned in the other Adverse Events section as well.
|
4-6 weeks after treatment / 1 year after treatment / 2 or 5 years after treatment
|
|
Incidence of Nervous System Events (Cumulative)
Tidsramme: 4-6 weeks after treatment / 1 year after treatment / 2 or 5 years after treatment
|
Any event within the MedDRA system organ class 'Nervous System disorders'.
Each incidence includes number shown at the previous time point, plus any new patients with the event.
|
4-6 weeks after treatment / 1 year after treatment / 2 or 5 years after treatment
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Patologiske processer
- Sygdomsegenskaber
- Infektioner
- Overførbare sygdomme
- Molekylære mekanismer for farmakologisk virkning
- Anti-infektionsmidler
- Enzymhæmmere
- Antineoplastiske midler
- Topoisomerase II-hæmmere
- Topoisomerasehæmmere
- Cytokrom P-450 enzymhæmmere
- Cytokrom P-450 CYP1A2-hæmmere
- Antibakterielle midler
- Ciprofloxacin
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 100201
- 2014-004622-18 (EudraCT nummer)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .